Physician profile
David D Byrd
NPI 1720173164
$7,298.58
in general payments reported to CMS, 2019-2025
41 companies · $650 in 2025
The $650 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $785 · 2020: $761 · 2021: $1,045 · 2022: $396 · 2023: $3,083 · 2024: $578 · 2025: $650.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,209 · Travel and Lodging: $2,102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,209.25 |
| Travel and Lodging | $2,102.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,796.43 | 2022-2025 | Intellis Adaptivestim, Inceptiv, Synchromedii |
| Relievant Medsystems, INC. | $1,308.49 | 2023 | Intracept |
| Boston Scientific Corporation | $694.98 | 2019-2025 | Intracept, Entrada, Wavewriter Alpha Prime 16 |
| Pfizer INC. | $481.92 | 2019-2021 | |
| Abbvie INC. | $456.06 | 2021-2025 | Ubrelvy |
| Collegium Pharmaceutical, INC. | $344.73 | 2019-2021 | |
| Nevro Corp. | $224.05 | 2019-2024 | Senza |
| Eisai INC. | $181.25 | 2020-2021 | |
| Amgen INC. | $167.63 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $142.88 | 2020-2024 | Austedo Xr |
| Abbott Laboratories | $128.38 | 2019-2025 | Proclaim, Eterna |
| Allergan, INC. | $126.64 | 2019-2022 | |
| Biodelivery Sciences International, INC. | $111.84 | 2019-2021 | |
| Nalu Medical, INC. | $99.07 | 2022-2023 | Nalu Neurostimulation System |
| Averitas Pharma INC. | $98.47 | 2024-2025 | Qutenza |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Byrd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.